Clinical Research Directory
Browse clinical research sites, groups, and studies.
Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer
Sponsor: European Institute of Oncology
Summary
This study is a prospective, non-interventional, open-label study to evaluate the glucose metabolism and the expression of the imaging agent 68 Gallium-Fibroblast Activation Protein Inhibitor-46 (68Ga-FAPi-46) with PET imaging, in woman affected by Breast Cancer (BC) and referred to diagnostic imaging work-up prior to primary therapy.
Official title: Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer. a Phase II Study to Evaluate the Comparison of 68Ga-FAPi-46 and 18F-FDG Uptake in Patients with Different Breast Cancer Subtypes
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
92
Start Date
2024-11-01
Completion Date
2025-11
Last Updated
2025-01-27
Healthy Volunteers
No
Interventions
68Ga-FAPi-46 PET/CT
Study participants will undergo baseline assessments at enrollment with 68Ga-FAPi-46 PET/CT
Locations (1)
European Institute of Oncology
Milan, Italy, Italy